Velocity Pharmaceutical Development, along with Dr John Nestor, had established Spitfire for the development of SP-1373, a potent GLP-1/Glucagon receptor co-agonist to treat non-alcoholic steatohepatitis (NASH). Under the
The post Altimmune to buy Presidio Partners portfolio firm Spitfire Pharma appeared first on Pharmaceutical Business review.
Original Article: Altimmune to buy Presidio Partners portfolio firm Spitfire Pharma